Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.

Noren NK, Foos G, Hauser CA, Pasquale EB.

Nat Cell Biol. 2006 Aug;8(8):815-25. Epub 2006 Jul 23. Erratum in: Nat Cell Biol. 2006 Sep;8(9):1038.

PMID:
16862147
2.

Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8. Epub 2004 Apr 5.

3.

Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells.

Hamada K, Oike Y, Ito Y, Maekawa H, Miyata K, Shimomura T, Suda T.

Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):190-7.

4.

The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.

Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A.

Cancer Res. 2010 Feb 1;70(3):1141-53. doi: 10.1158/0008-5472.CAN-09-1710. Epub 2010 Jan 19.

5.

EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.

Sturz A, Bader B, Thierauch KH, Glienke J.

Biochem Biophys Res Commun. 2004 Jan 2;313(1):80-8.

PMID:
14672701
6.

BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.

Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, Hayakawa F, Ito Y, Katsumi A, Yamamoto K, Emi N, Kiyoi H, Naoe T.

Eur J Haematol. 2010 Mar;84(3):229-38. doi: 10.1111/j.1600-0609.2009.01387.x. Epub 2009 Nov 28.

PMID:
20002159
7.

Expression of Ephb2 and Ephb4 in breast carcinoma.

Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM.

Pathol Oncol Res. 2004;10(1):26-33. Epub 2004 Mar 18.

8.

The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.

Yang NY, Pasquale EB, Owen LB, Ethell IM.

J Biol Chem. 2006 Oct 27;281(43):32574-86. Epub 2006 Aug 31.

9.

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.

Cancer Res. 2007 Feb 15;67(4):1580-8.

10.

Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS.

Am J Pathol. 2006 Jul;169(1):279-93.

11.

Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.

Kain KH, Gooch S, Klemke RL.

Oncogene. 2003 Sep 4;22(38):6071-80.

PMID:
12955086
12.
13.

The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernández-Losa J, Castaño J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S Jr, Arango D.

Cancer Res. 2009 Sep 15;69(18):7430-8. doi: 10.1158/0008-5472.CAN-09-0706. Epub 2009 Sep 8.

14.

Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes.

Kain KH, Klemke RL.

J Biol Chem. 2001 May 11;276(19):16185-92. Epub 2001 Jan 19.

15.

Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.

Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I.

Oncol Rep. 2001 May-Jun;8(3):567-73.

PMID:
11295082
16.

Cell adhesion to ephrinb2 is induced by EphB4 independently of its kinase activity.

Sakamoto H, Zhang XQ, Suenobu S, Ohbo K, Ogawa M, Suda T.

Biochem Biophys Res Commun. 2004 Aug 27;321(3):681-7.

PMID:
15358160
17.

Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.

Kwan Tat S, Pelletier JP, Amiable N, Boileau C, Lajeunesse D, Duval N, Martel-Pelletier J.

Arthritis Rheum. 2008 Dec;58(12):3820-30. doi: 10.1002/art.24029.

18.

The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.

Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS.

Blood. 2009 Jan 1;113(1):254-63. doi: 10.1182/blood-2008-02-140020. Epub 2008 Oct 3.

19.

EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.

20.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
Items per page

Supplemental Content

Write to the Help Desk